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In 2006, Belgium was the first country in the European 
Union to recommend rotavirus vaccination in the rou-
tine infant vaccination schedule and rapidly achieved 
high vaccine uptake (86–89% in 2007). We used 
regional and national data sources up to 7 years post-
vaccination to study the impact of vaccination on labo-
ratory-confirmed rotavirus cases and rotavirus-related 
hospitalisations and deaths.  We showed that (i) from 
2007 until 2013, vaccination coverage remained at 
79–88% for a complete course, (ii) in children 0–2 
years, rotavirus cases decreased by 79% (95% confi-
dence intervals (CI): 68–89%) in 2008–2014 compared 
to the pre-vaccination period (1999–2006) and by 50% 
(95% CI: 14–82%) in the age group ≥ 10 years, (iii) hos-
pitalisations for rotavirus gastroenteritis decreased 
by 87% (95% CI: 84–90%) in 2008–2012 compared to 
the pre-vaccination period (2002–2006), (iv) median 
age of rotavirus cases increased from 12 months to 
17 months and (v) the rotavirus seasonal peak was 
reduced and delayed in all post-vaccination years. The 
substantial decline in rotavirus gastroenteritis requir-
ing hospitalisations and in rotavirus activity following 
introduction of rotavirus vaccination is sustained over 
time and more pronounced in the target age group, but 
with evidence of herd immunity.
Introduction
Globally, rotavirus is the leading cause of severe acute 
gastroenteritis in children aged less than 5 years, 
resulting in substantial morbidity and mortality [1]. 
Most children are infected at least once with rotavirus 
by the age of 5 years, with severe disease occurring 
most commonly between the ages of 6 months and 
2 years [2,3]. Before vaccine introduction in Belgium 
in 2006, the burden of rotavirus disease was high 
compared with other European countries and rotavi-
rus was estimated to account for nearly 5,600 hospi-
talisations annually in children < 7 years [4]. In June 
2006, the two-dose oral monovalent vaccine (Rotarix, 
GlaxoSmithKline Biologicals, Rixensart, Belgium) was 
marketed, followed by the three-dose oral pentavalent 
vaccine (RotaTeq, Sanofi Pasteur MSD, Lyon, France) 
in June 2007. Rotavirus vaccination has been recom-
mended by the Superior Health Council (the Belgian 
National Immunization Technical Advisory Group) for 
all infants at 8 weeks of age since October 2006 and 
has been partially reimbursed since November 2006. 
The monovalent vaccine is administered at 8 and 12 
weeks of age and the pentavalent vaccine at 8, 12 
and 16 weeks of age. Since January 2007, rotavirus 
vaccination has been offered systematically during 
preventive consultations organised by the govern-
ment agency well-baby clinics. All children between 
0 and 3 years are actively invited via their parents or 
guardians to attend these easily accessible consulta-
tions in their local community, free of charge (including 
medical acts like prescribing and administering vac-
cines). Unlike other recommended childhood vaccines, 
rotavirus vaccines are only partially reimbursed on a 
per-prescription basis. Currently, EUR 11.8 per dose 
is co-paid by caregivers (usually the parents) of vac-
cine recipients [5]. Rotavirus vaccine introduction led 
to a substantial decline in rotavirus activity during the 
period from July 2007 to June 2008 [6] and a reduction 
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in rotavirus-related hospitalisations in the period from 
June 2007 to May 2009, based on a sample of 12 hos-
pitals in Belgium and on a study in a university hos-
pital [7,8]. A case–control study conducted in Belgium 
in 2008–2010 showed that the effectiveness of two 
doses of the monovalent rotavirus vaccine against hos-
pital admissions was 90% [9].
Rotavirus gastroenteritis is not mandatorily notifi-
able in Belgium. Surveillance is conducted through a 
laboratory-based sentinel network registering positive 
rotavirus tests, and the secondary analysis of health-
care utilisation databases (rotavirus-related hospitali-
sations, for which registration is obligatory). Rotavirus 
vaccine coverage is monitored through cluster sample 
surveys [10,11]. We collected all available surveillance 
and coverage data (one regional and seven national 
data sources) to study the impact of rotavirus vaccina-
tion in more detail and for a longer follow-up period. 
More particularly, we assessed trends in rotavirus test-
ing and detection, hospitalisations and deaths due to 
rotavirus or acute gastroenteritis and rotavirus vacci-
nation coverage. We analysed weekly rotavirus activity 
for up to 7 epidemiological years (1 July to 30 June) after 
vaccine introduction, described changes in both timing 
and age of rotavirus infection, obtained evidence for 
herd immunity, looked for changes in testing behaviour 
pre- and post-vaccination and estimated the coverage 
of the two rotavirus vaccines separately.
Methods
Data were derived from eight different databases, sur-
veillance systems and other data sources in Belgium 
(Table 1). Data analysed include: vaccination cover-
age, number of rotavirus tests and confirmed infec-
tions, hospitalisations and deaths due to rotavirus or 
acute gastroenteritis. All data were processed without 
patient-identifying information. We assigned a random 
number (one, two or three tests) to weeks in which 
the exact number of tests/confirmed infections/hos-
pitalisations could not be disclosed to us for privacy 
reasons under Belgian legislation (e.g. fewer than four 
tests). Analyses were performed using R [12] and SAS 
Enterprise Guide (version 5.1).
Vaccination coverage
Vaccination coverage was derived from three inde-
pendent sources: coverage surveys, vaccination sales 
data and reimbursement data.
Coverage surveys: in Belgium vaccination coverage in 
children is estimated in the three regions (Brussels-
Capital region, Flanders and Wallonia) based on cluster 
sample surveys [10,11]. We estimated a national cover-
age for 2012 as a weighted average of the three regional 
rates, using the population under 1 year of age of every 
region of the corresponding year. Population and birth 
statistics were retrieved from Statistics Belgium [13].
Vaccination sales data: the annual number of doses 
sold in Belgium was obtained from GlaxoSmithKline 
Biologicals s.a (Rotarix) and Sanofi Pasteur MSD 
Figure 1
Weekly number of laboratory confirmed rotavirus cases and rotavirus hospitalisations in children aged 0–2 years, and 
annual rotavirus vaccine coverage for a complete schedule based on reimbursement data, sales data and surveys, Belgium, 
various seasons 1999–2014
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Figure 2
Number of confirmed rotavirus cases and hospitalisations by age and rotavirus season, Belgium, various seasons, July 2004 
to June 2014
Age 0 years
A. Confirmed rotavirus cases, July 2004 to June 2014a
B. Rotavirus hospitalisations, July 2004 to June 2012b
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(RotaTeq). We assumed all doses sold were adminis-
tered and all infants received a complete vaccination 
schedule (i.e. two doses for Rotarix or three doses for 
RotaTeq). Annual vaccination coverage was estimated 
by dividing the number of complete vaccination sched-
ules by the number of newborns in the corresponding 
year. Since Rotarix was put on the market on 1 June 
2006, coverage for 2006 was based on the corre-
sponding monthly birth statistics over the remaining 7 
months.
Reimbursement data: the number of partially reim-
bursed rotavirus vaccines in Belgium was obtained 
from the Inter Mutualistic Agency (IMA-AIM). These 
Figure 3
Rotavirus hospitalisations, rotavirus laboratory confirmed cases and proportion of rotavirus positive tests, Belgium, 
1999–2014
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For each rotavirus season, width (vertical line) and peak (point) of the rotavirus epidemic are shown.
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reimbursement data allowed us to derive the number 
of infants who had received at least one rotavirus vac-
cine dose and the number of infants who had com-
pleted a course of vaccination by week (i.e. two doses 
Rotarix or three doses RotaTeq). IMA-AIM data contain 
the delivery date of the vaccine (i.e. date of purchase), 
which is not necessarily the administration date. It was 
estimated that 70% of infants receive rotavirus vac-
cine within one week after purchase and 90% within 
4 weeks of purchase (for all doses, unpublished data 
from Vaccinnet [14]). Annual vaccination coverage was 
calculated by dividing the number of infants with a 
complete vaccination scheme reimbursed, by the num-
ber of vaccine-eligible infants of the same year.
Number of rotavirus tests and laboratory-
confirmed rotavirus infections
Confirmed rotavirus cases were obtained from the 
Sentinel Laboratory Network (SLN). The SLN is a vol-
untary network of microbiology laboratories that 
weekly reports positive results of ca 40 pathogens to 
the Belgian Scientific Institute of Public Health and 
that is representative in terms of test coverage at both 
the national and regional level (Flanders, Wallonia and 
Brussels) [15]. Rotavirus infection was included in the 
SLN surveillance in 1999, discontinued in 2001 and 
reintroduced in 2005. The discontinuation in surveil-
lance from 2001 to 2004 was due to the withdrawal of 
the RotaShield vaccine (Wyeth Laboratories, Inc., PA, 
US) and the high workload related to case reporting 
for the laboratories [6]. The percentage of all rotavirus 
tests in Belgium covered by the SLN was stable and 
estimated at 66.1% (average 2006–2012; range 64.5–
67.5%). For each positive test, a minimum set of epide-
miological data are provided, including date of birth, 
sex, municipality of the case, date of detection, type of 
sample and laboratory technique used. No clinical or 
vaccination data are collected. We obtained the weekly 
number of positive rotavirus tests by age, as registered 
by the SLN for the years 1999–2001 and 2005–2014.
Table 1
Data sources and available time periods to determine the impact of rotavirus vaccination, Belgium, 1987–2014
Datasource Abbreviation Indicator
Available 
time 
period
Geographical 
coverage
National 
coverage Pre-vaccination
Transition 
period
Post-
vaccination
Sentinel Laboratory 
Network SLN
Laboratory 
confirmed 
rotavirus infections
1999–2001 
and 
2005–2014
Nationwide
66.1% 
(average 
2006–2012)
July 1999 to 
June 2001 and 
July 2005 to 
June 2006
July 2006 
to June 
2008
July 2008 to 
June 2014
Minimal 
Hospitalization Data MHD
Hospitalisation 
discharge 
for rotavirus 
and all cause 
gastroenteritis 
ICD-9 (ICD-9-CM)
1999–2011 Nationwide 100% July 1999 to June 2006
July 2006 
to June 
2008
July 2008 to 
June 2011
Carenet-National 
Alliance of Christian 
Sickness Funds
Carenet-NCSF
Health insurance 
data on hospital 
admissions 
for rotavirus 
gastroenteritis 
(rota or ICD-9-CM 
or ICD-10)
2004–2012 Nationwide
41.3% 
(average 
2004–2012)
July 2004 to 
June 2006
July 2006 
to June 
2008
July 2008 to 
June 2012
Inter Mutualistic 
Agency IMA-AIM
Number of 
reimbursed 
rotavirus tests 
and reimbursed 
vaccines 
(vaccination 
coverage)
2004–2012 Nationwide 100% July 2004 to June 2006
July 2006 
to June 
2008
July 2008 to 
June 2012
Sales data NA
Number of vaccines 
sold (vaccination 
coverage)
2006–2013 Nationwide 100% NA 2006–2008 2008–2013
Weighted average of 
coverage surveys NA
Vaccination 
coverage 2012 Nationwide 100% NA NA 2012
Standardized 
Procedures for 
Mortality Analysis
SPMA
Deaths due to 
gastroenteritis 
(ICD-9-CM or 
ICD-10)
1987–
2000 and 
2003–2010
Nationwide 100% 1987–2000 2003–2005
2006–
2008 2009–2010
Cause-specific 
mortality Flanders NA
Deaths due 
to rotavirus 
gastroenteritis 
(ICD-10)
2000–2012 Regional
54% 
(average 
2000–2012)
2000–2005 2006–2008 2009–2012
NA: not applicable.
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Table 2
Impact of vaccination on laboratory confirmed rotavirus infections and hospitalisations for acute gastroenteritis and 
rotavirus gastroenteritis by age strata according to different data sources used, Belgium, various seasons 1999 to 2014
Rotavirus positive testsa and reimbursed testsb
Pre-vaccination period Transition period Post-vaccination period 
Mean 
rotavirus 
positive 
tests (%)  
July 1999 to 
June 2001 
and July 
2005 to June 
2006 
Mean 
re-imbursed 
rotavirus tests 
(%)  
July 2004 to June 
2006 
Mean rotavirus 
positive tests 
(%)  
July 2006 to 
June 2008 
Mean 
re-imbursed 
rotavirus tests 
(%)  
July 2006 to 
June 2008 
Mean rotavirus 
positive tests 
(%)  
July 2008 to 
June 2014 
Mean 
re-imbursed 
rotavirus tests 
(%)  
July 2008 to 
June 2012 
Reduction 
of rotavirus 
positive 
tests (%)
(post/pre) 
95% CI 
Reduction of 
re-imbursed 
rotavirus tests 
of SNL (%) 
(post/pre) 
95% CI 
0–2 yearsc 6,890 47,742 3,581 40,569 1,434 32,947 79.2% 68.0–88.9 31.0%
15.6–
43.0
0–11 months 3,585 (52.7%) 13,216 (27.5%) 1,408 (40.1%) 11,265 (27.8%) 592 (41.5%) 9,824 (29.8%) 83.5%
75.8–
90.5 25.7%
14.2–
35.6
12–23 months 2,477 (36.4%) 24,662 (51.6%) 1,559 (44.3%) 20,636 (50.9%) 601 (42.1%) 16391 (49.7%) 75.7% 61.3–87.7 33.5%
18.4–
45.1
24–35 months 735 (10.8%) 9,864 (20.9%) 549 (15.6%) 8,669 (21.4%) 236 (16.5%) 6,732 (20.4%) 68.0% 39.8–85.9 31.8%
7.2–
48.1
3 years and 
older 558 NA 405 NA 288 NA 48.5% 14.9–73.5 NA NA
3 years 255 (45.6%) NA 178 (44.0%) NA 110 (38.3%) NA 56.7% 23.0–79.8 NA NA
4 years 102 (18.3%) NA 79 (19.5%) NA 54 (18.8%) NA 47.2% 9.3–75.7 NA NA
5-9 years 103 (18.4%) NA 81 (19.9%) NA 74 (25.8%) NA 27.8%
CI 
includes 
0
NA NA
10 years and 
older 99 (17.7%) NA 67 (16.6%) NA 49 (17.1%) NA 50.0% 13.9–82.1 NA NA
5 years and 
older 201 NA 148 NA 124 NA 38.7% 1.4–69.2 NA NA
Total 7,448 NA 3,985 NA 1,722 NA 76.9% 64.4–87.6 NA NA
Hospitalisation discharge datad 
Pre-vaccination  
July 1999 to June 2006 
Transition period  
July 2006 to June 2008 
Post-vaccination period  
July 2008 to June 2011 
Mean annual 
number 
Mean incidence 
rate per 
100,000 
Mean annual 
number 
Mean incidence 
rate per 100,000 
Mean annual 
number 
Mean 
incidence rate 
per 100,000 
Reduction 
incidence 
(post/pre) 
95% CI 
Rotavirus 
gastroenteritis 4,761 46.0 2,617 24.7 1,328 12.3 73.3% 70.1–75.8
Acute 
gastroenteritis 22,550 218.1 19,843 187.4 17,211 159.3 26.9% 22.1–31.4
Hospitalisations health insurance datae 
Pre-
vaccination  
July 2004 to 
June 2006 
Transition 
period  
July 2006 to 
June 2008 
Post-
vaccination  
July 2008 to 
June 2012 
Reduction 
(post/pre) 95% C) 
Mean annual 
number % 
Mean annual 
number % 
Mean annual 
number % 
0-2 years 6,399 2,393 842 86.8% 84.1–89.5
0-11 months 3,038 47.5% 948 39.6% 337 40.0% 88.9% 86.2–91.5
12-23 months 2,522 39.4% 1,012 42.3% 340 40.4% 86.5% 81.9–90.3
24-35 months 839 13.1% 432 18.1% 165 19.6% 80.3 63.8–89.8
3 years and 
older 665 339 231 65.2% 50.2–76.1
3 years 344 51.7% 182 7.6% 105 45.5% 69.5 CI includes 0
4 years 120 18.0% 70 2.9% 51 22.1% 57.6 CI includes 0
5-9 years 161 24.2% 74 3.1% 61 26.4% 62.3 35.2–80.8
10 years and 
older 41 6.2% 14 0.6% 15 6.5% 63.3 CI includes 0
5 years and 
older 201 87 76 62.5 49.3–74.2
Total 7,064 2,732 1,074 84.8% 81.6–87.9
CI: Confidence intervals; NA: not available.
a Source: Sentinel Laboratory Network.
b Source: Inter Mutualistic Agency.
c In those 0-2 years the age in months was unknown in some cases.
d Source: Minimal Hospitalization Data.
e Source: Carenet-National Alliance of Christian Sickness Funds.
Reduction of disease post-vaccination is given with 95% confidence intervals.
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To investigate whether a reduction in number of posi-
tive rotavirus tests was due to an actual reduction in 
number of rotavirus cases or merely due to changes 
in testing behaviour since the introduction of the rota-
virus vaccines, we additionally collected the weekly 
number of reimbursed rotavirus tests performed by 
the SLN and by all laboratories in Belgium. Data were 
obtained from IMA-AIM, which registers all reimbursed 
microbiology tests per laboratory in Belgium. Rotavirus 
tests have been reimbursed for children ≤ 2 years of age 
since 1995. Weekly numbers of reimbursed rotavirus 
tests were obtained for the period 2004–2012. For the 
years 2004 and 2005 reimbursement data were only 
available for the ‘Permanent Sample’ (PS) from IMA-
AIM, a representative sample which covers 2.5% of the 
total ensured population (in Belgium health insurance 
is mandatory). These data were extrapolated to the 
population based on the average coverage of the PS for 
the years 2006–2011 (for which data for both PS and 
the total ensured population were available). During 
the period 2006–2011, PS coverage did not change 
over time. The age of children with a reimbursed rota-
virus test could not be reliably obtained from IMA-
AIM, as only the year of birth is available. Therefore, 
the week-by-week age distribution of children < 2 years 
for whom tests were reimbursed was obtained from 
the largest health insurance company in Belgium (the 
National Alliance of Christian Sickness Funds (NCSF)). 
The NCSF covers ca 40% of all members of the ensured 
population included in IMA-AIM in a representative 
manner [16]. This age distribution was applied to the 
overall weekly number of reimbursed tests performed 
by the SLN. Data extractions and analyses related to 
NCSF were performed at the Medical Management 
Department of the NCSF under the supervision of the 
Chief Medical Officer.
Additionally, we calculated the weekly proportion 
of rotavirus tests that were positive by dividing the 
number of positive tests (SLN) by the number of reim-
bursed tests (IMA-AIM), for children ≤ 2 years of age. 
As children may be tested more than once for rotavirus 
(including multiple tests for a single episode), we iden-
tified and removed the duplicates in the SLN, IMA-AIM 
and NCSF databases, based on date of birth, sample 
week and municipality if available. Any episode occur-
ring in the same child in the same year was considered 
to be a duplicate case.
Hospitalisations for rotavirus and acute 
gastroenteritis
Rotavirus-related hospitalisations were obtained from 
two independent databases.
Minimal Hospital Data
The Minimal Hospital Data (MHD) are managed by the 
Federal Public Service of Health and are an electronic 
collection of anonymised records of patients admitted 
to all public and private hospitals in Belgium. For the 
period 1999–2011, we obtained the monthly number of 
hospitalisations with primary discharge diagnoses of: 
(i) rotavirus enteritis (by diagnosis code International 
Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9-CM) code 008.61) and (ii) any other 
acute gastroenteritis not coded as rotavirus (i.e. diar-
rhoea of determined aetiology (bacterial (001–005 and 
008.0–008.5), parasitic (006–007) and viral (008.6)), 
and/or diarrhoea of undetermined aetiology (presumed 
infectious (008.8–009.3)) [17]. Hospitalisation rates 
were calculated by dividing the annual number of rota-
virus enteritis or acute gastroenteritis hospitalisations 
by the age-specific Belgian population for the corre-
sponding years [13]. Because the age of a hospitalised 
person could not be derived reliably from MHD (only 
year of birth is registered), the Carenet-NCSF database 
was used to investigate the age distribution of rotavi-
rus-related hospitalisations (see next paragraph).
Hospital database Carenet-NCSF
Carenet is designed for electronic information exchange 
between hospitals and health insurance companies 
about hospital admissions. In July 2006 Carenet cov-
ered 88% of Belgian hospital beds, in July 2009 this 
increased to 99%. We could only obtain Carenet data 
from members of the NCSF health insurance company 
(see above). We obtained all records (2004–2012) on 
hospitalised patients who were member of the NCSF for 
which the diagnostic field included one of the follow-
ing search strings: ‘rota’ or ICD-9-CM code ‘008.61’ or 
ICD-10 code ‘A08.0’ [18]. A medical clinician searched 
the diagnostic fields of the retrieved records manually 
and selected those for which rotavirus was likely to be 
the main reason for hospitalisation. Data extractions 
and analyses related to NCSF were performed at the 
Medical Management Department of the NCSF under 
the supervision of the Chief Medical Officer.
Weekly numbers of rotavirus hospitalisations from 
NCSF members were used to cross-validate trends 
observed in MHD, to investigate the age distribution of 
rotavirus hospitalisations and to study a possible shift 
in the peak number of hospitalisations after the intro-
duction of rotavirus vaccination.
Deaths due to gastroenteritis
We calculated the death rate in children < 5 years due 
to gastroenteritis using the Standardized Procedures 
for Mortality Analysis (SPMA) website [19]. Data were 
available for 1987–2000 and 2003–2010. We included 
all intestinal infectious diseases with ICD-9 codes 
001–009. From 1998 onwards ICD-10 codes A00-A09 
were used. More detailed coding of mortality data were 
available for Flanders for the period 2000–2012 allow-
ing the use of ICD-10 codes (A00-A09) and the specific 
code for rotavirus (A08.0) [20]. The annual death rate 
was defined as the ratio of the number of deaths to the 
number of people in the age group < 5 years.
General definitions and assumptions
We defined epidemiological years from the beginning of 
July to the end of June of the following year. We defined 
three periods of analysis to reflect the introduction 
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of rotavirus vaccination. The pre-vaccination period 
includes data from July 1999 (MHD, SLN) and July 2004 
(Carenet-NCSF, IMA-AIM) until June 2006 (all datasets). 
The transition period, during which rotavirus vaccine 
was first marketed and introduced, includes data from 
July 2006 to June 2008. The post-vaccination period 
includes data from July 2008 (all datasets) until June 
2011 for MHD, June 2012 for Carenet-NCSF and IMA-AIM 
and June 2014 for the SLN (Table 1).
Currently, there is no standard way to determine the 
onset, peak and end of a rotavirus epidemic. Indeed, 
the European Centre for Disease Prevention and 
Control (ECDC) advises that each country specifies its 
own definition [21]. To explore the changes in timing 
and the duration of the rotavirus epidemic, we defined 
the start and end of the rotavirus epidemic as the week 
in which more or less than the average weekly num-
ber of positive rotavirus tests occurred for a particular 
epidemiological year (‘method average’). We also used 
the definition proposed by Tate and colleagues (‘Tate 
method’) [22], and recommended by the ECDC when 
the proportion of positive rotavirus laboratory tests is 
available. This method defines the start and end of the 
epidemic for each epidemiological year as the 2 first or 
last consecutive weeks during which the proportion of 
positive tests is ≥ 10%. The peak of the epidemiological 
year was defined as the week with the highest number 
of positive rotavirus tests or rotavirus hospitalisations 
or proportion of rotavirus positive tests.
We estimated the vaccine impact, expressed as the 
percentage change, by comparing the mean number of 
laboratory confirmed and hospitalised rotavirus cases 
in unvaccinated populations (pre-vaccination period) 
to the mean in vaccinated populations (post-vaccina-
tion period) [23]. Confidence intervals were calculated 
using Fieller’s method for the confidence interval of 
the quotient of two means, assuming Gaussian distri-
butions [24].
Results
Vaccination coverage
Coverage surveys: national coverage in 2012 was esti-
mated at 85.8% (95% CI: 83.0–88.2%) for a two- or 
three-dose schedule and 89.4% (95% CI: 87.1–91.6%) 
for recipients of at least one dose (Figure 1).
Vaccination sales data: in the first 7 months follow-
ing vaccine introduction, vaccination coverage (two- or 
three-dose scheme) in infants < 1 year was 32.5% and 
rapidly increased to reach 89.4% in 2013, with an aver-
age of 87.5% (minimum-maximum (minmax) range: 
85.5–89.4%) for 2007–2013 (Figure 1).
Reimbursement data: between 2007 and 2012, on 
average 85.4% (range: 80.7–88.2%) of eligible infants 
were vaccinated against rotavirus (88.0% (range: 
80.5–99.0%) of them with Rotarix and 12.0% (min max 
range: 9.5–19.5%) with RotaTeq, Figure 1). Of these 
vaccinated infants, 9.3% did not complete the two- or 
three-dose scheme. This percentage slightly decreased 
from 10.8% in 2007 to 7.9% in 2012, and is larger for 
the three-dose vaccine (RotaTeq) than for the two-dose 
vaccine (Rotarix) (17.3% vs 6.8% in 2012). The propor-
tion of infants vaccinated with RotaTeq (vs Rotarix) 
increased after its introduction up to 19.5% in 2010 
and decreased thereafter, to reach 10.6% at the end of 
2012.
Number of rotavirus tests and laboratory-
confirmed rotavirus infections
We excluded 44,284 (24.2%) reimbursed tests from 
the IMA-AIM database and 2,571 (6.0%) laboratory-
confirmed infections from the SLN because these were 
considered duplicates.
The number of laboratory-confirmed rotavirus infec-
tions in children 0–2 years of age decreased by 79.2% 
after widespread vaccination (Figure 1 and 2a, Table 
2), whereas the number of reimbursed rotavirus tests 
decreased only by 31.0% (Table 2). The proportion of 
positive tests in the SLN decreased from 24.8% (pre-
vaccination period) to 7.4% (post-vaccination period) 
for children 0–2 years and from 45.5% to 10.1% for 
infants < 1 year.
The reduction of rotavirus infections was highest in 
infants below 1 year of age with 80.1% (95% CI: 72.1–
87.7) reduction in infants 0–5 months and 85.8% (95% 
CI: 78.1–92.4) reduction in infants 6–11 months of age. 
A substantial reduction was seen in the age groups 
too old to be protected directly by vaccination (i.e. evi-
dence for herd immunity, Figure 2a). In the age group 
of 10 years and older, the reduction was 50.0% (Table 
2).
The median age of a person tested positive for rota-
virus increased from 12 months pre-vaccination to 17 
months post-vaccination. In the pre-vaccination period 
there were more positive tests in infants 6–11 months 
of age (59.7%) than in 0–5 months (40.3%), while in the 
post-vaccination period this difference almost disap-
peared (51.3% in infants 6–11 months of age and 48.6% 
in 0–5 months). After the introduction of the rotavirus 
vaccination programme, a larger proportion of posi-
tive rotavirus tests occurred in children 12 months and 
older (Table 2). The age distribution of the number of 
tests reimbursed for rotavirus did not change much fol-
lowing widespread vaccination (Table 2).
The peak month of laboratory-confirmed rotavirus 
cases shifted from February in the pre-vaccination 
period to April after vaccination (Figure 3). The maxi-
mum weekly number of cases dropped by 77.8% (95% 
CI: 74.4–80.9%), from 633 cases pre-vaccination to 141 
post-vaccination (Figure 1). The impact of vaccination 
on the duration of the rotavirus epidemics depends 
on the method used to determine this duration: with 
our approach (‘method average’), no clear change was 
observed, but with the method used by Tate et al. [22], 
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post-vaccination epidemics were found to be 10 weeks 
shorter than pre-vaccination (Figure 3). Testing behav-
iour (distribution of the number of rotavirus reimbursed 
tests over an epidemiological year) did not change after 
the introduction of the vaccines (results not shown).
Hospitalisations
Based on the discharge data (MHD), the overall num-
ber of rotavirus-related hospitalisations decreased 
by 73.3% after widespread vaccination (Table 2). 
During the pre-vaccination period, the mean incidence 
of rotavirus hospitalisations was 46.0 per 100,000 
person-years (range: 41.7–53.5), compared with 12.3 
per 100,000 person-years (range: 11.7–12.9) in the 
post-vaccine period (Table 2). The largest reduction 
occurred in infants 6–11 months of age (90%, Carenet-
NCSF), but a substantial reduction was also seen in 
persons too old to be protected directly by vaccination 
(Figure 2b). Before vaccination, one-third (29.2%) of 
children hospitalised for rotavirus were 6–11 months 
old. After vaccination, only one-fifth (18.3%) of rotavi-
rus-related hospitalisations occurred in this age group. 
Furthermore, 43.0% of all hospitalisations occurred in 
infants aged 0–11 months old in the pre-vaccination 
period, compared with 31.4% in the post-vaccination 
period.
Peak number of rotavirus-related hospitalisations 
shifted from February to April in the post-vaccination 
period (Figure 3). The width of the epidemic (based on 
the ‘method average’) did not change.
The mean incidence of all-cause acute gastroenteritis 
hospitalisations decreased by 26.9% (95% CI: 22.1–
31.4%) between the pre- and post-vaccination period 
(MHD, Table 2). In the pre-vaccination period, rotavirus 
infections occurred in 21.1% (range: 20.0–23.1%) of 
hospitalisations for acute gastroenteritis, in contrast to 
7.7% (range: 7.1–8.2%) in the post-vaccination period.
Deaths due to gastroenteritis
In the period 1987–2005, between one and seven 
deaths per year occurred in children < 5 years due to 
gastroenteritis, representing a death rate of 0.7 per 
100,000 per year (range 0.2–1.1). In the post-vaccina-
tion period (2008–2010), the annual number of deaths 
varied between zero and three deaths per year (death 
rate: 0.2/100,000).
Based on the more detailed information in the region 
of Flanders (average population of 322,356 children < 5 
years), rotavirus was responsible for two deaths during 
2000–2005, one death in the period 2006–2008 and 
no deaths during 2009–2012.
Discussion
During the 7 years following rotavirus vaccine introduc-
tion, we established that: (i) vaccine uptake remained 
high; (ii) the substantial decline in both rotavirus-
related hospitalisations and laboratory-confirmed 
rotavirus persisted; (iii) rotavirus incidence peaked 
annually in spring instead of winter; (iv) the average 
age at infection and hospitalisation increased and (v) 
the number of laboratory-confirmed and hospitalised 
rotavirus cases decreased also in unvaccinated per-
sons (evidence for herd immunity).
The estimated vaccination coverage was consistently 
high using different data sources. We found that on 
average 9.3% of Belgian infants did not complete their 
schedule, which is higher than the 2% found by a cov-
erage survey conducted in Flanders [10]. However in 
Flanders, coverage and compliance with vaccinations 
are typically higher than in the other regions [10], and 
this Flemish survey considered two doses as fully vac-
cinated whereas a complete schedule with RotaTeq 
consists of three doses. Also, we found that the pro-
portion of infants who completed the series was higher 
for the two-dose than the three-dose vaccine, similar 
to findings in the United States (US) [25-27].
In the pre-vaccination period, we estimate that rotavi-
rus infections were responsible for 21.1% of hospital 
admissions for acute gastroenteritis, which is in line 
with previous European estimates (21–58% [28-30]). 
We found a substantial decrease in laboratory-con-
firmed cases and rotavirus-related hospitalisations and 
deaths in the post-vaccination period, which confirms 
the reduction of 87% of rotavirus hospitalisations pre-
dicted by a mathematical model assuming uptake rates 
similar to those for other routine infant vaccinations 
[31]. Furthermore, this considerable reduction is in line 
with the high effectiveness of the rotavirus vaccines 
(over 85%) [32]. A systematic review of ecological stud-
ies from eight countries reported a 49–89% decline in 
laboratory-confirmed rotavirus hospital admissions in 
children less than 5 years old within 2 years of vaccine 
introduction [33]. The evidence for a direct vaccination-
related reduction is further strengthened by a lower 
proportion of rotavirus-positive tests in infants < 1 year 
following rotavirus vaccine introduction, i.e. a decrease 
from 45.5% to 10.1%.
In addition, the typical rotavirus seasonal peak appar-
ent in winter and early spring before introduction 
of the vaccine was reduced and delayed in all post-
vaccination years. Although pre-vaccination this was 
based on data from only 3 (laboratory tests) or 2 (hos-
pitalisations) epidemiological years, these results 
pointed in the same direction for both. These changes 
in seasonal patterns are unlikely to be due to year-to-
year variations, and probably reflect a decline in virus 
transmission, as predicted by mathematical modelling 
applied to England and Wales [34]. In the Netherlands, 
where a rotavirus vaccination programme is absent, 
the peak rotavirus incidence was exceptionally low 
in 2013–14 [35]. The authors offered as explanations 
the low birth rate, mild winter, high rotavirus inci-
dence in the previous year and the introduction of 
rotavirus vaccination in neighbouring countries. Also 
in Belgium we found the number of rotavirus posi-
tive tests in 2013–14 to be lower than in any of the 
10 www.eurosurveillance.org
previous epidemiological years, although much less 
pronounced than in the Netherlands. During that epi-
demiological year, birth rate, vaccination coverage and 
rotavirus testing behaviour did not change compared 
with the previous epidemiological years, and no excep-
tionally high rotavirus peak preceded 2013–14 [13]. 
Besides, although 2013–14 was characterised by an 
exceptionally warm winter, this was also the case for 
2006–07 and 2007–08 [36]. Hence, the explanations 
proposed for the extremely low rotavirus incidence in 
the Netherlands in 2013–14 seem unlikely to explain 
the low incidence in Belgium in the same epidemiologi-
cal year. Clearly, more research is needed to get insight 
in the cause(s) of rotavirus annual variations, both in 
the presence and absence of vaccination. The impact 
of vaccination on the average length of the rotavirus 
epidemic is difficult to determine due to the lack of a 
standard method to measure this length. According to 
our calculation method, the length of the yearly rota-
virus epidemic was unchanged by the introduction of 
the vaccines. Yet, the method described by Tate and 
colleagues [22] suggests a 10-week decrease. Note 
that comparison between the two methods is difficult 
as only one pre-vaccination epidemiological year was 
available for the proportion of rotavirus tests being 
positive. We did not observe clear biennial increases in 
rotavirus activity in the post-vaccine era as observed 
in the US [22]. This might be due to different trans-
mission patterns resulting from the lower speed and 
level of vaccine uptake in the US vs Belgium. In the US, 
rotavirus vaccines have been recommended for routine 
use since 2006 and coverage (of mainly the three-dose 
vaccine) increased gradually from 44% in 2009 to 73% 
in 2013 for a complete schedule [37], whereas vaccina-
tion coverage in Belgium increased to 79–88% within 7 
months. The free of charge, low-threshold community 
outreach vaccination for Belgian infants (together with 
using predominantly the two-dose rotavirus vaccine) 
could lead to higher vaccination coverage and better 
completion rates. Another reason could be that the two 
vaccines differ in strain composition and may therefore 
exert different pressures on the circulating serotypes 
and overall transmission dynamics. It remains difficult, 
however, to explain differences in cycling patterns: 
modelling studies show that small changes in rotavi-
rus transmission dynamics can lead to very different 
cycling patterns [38,39].
We observed an increase in the median age of con-
firmed rotavirus cases. This was predicted by a model 
applied to England and Wales, based on vaccination 
coverage of 91% [34]. We did not observe an increase 
in hospitalisations in older children, in contrast to the 
findings in Austria, where during the fourth year post-
vaccination an increase of 48% in hospitalisation rates 
for rotavirus was observed in children 5–9 years of 
age [40]. Such increase was also predicted by models 
assuming the probability of infection to depend on the 
number of previous infections, and not on age [38,39]. 
Paulke-Korinek and colleagues mention that the inci-
dence increase in Austria could also be due to very high 
rotavirus activity in 2011 [40]. In Belgium, an increased 
rotavirus activity was noted in 2012–13 compared with 
the previous epidemiological year (Figure 2a), but it is 
not known if this is reflected in an increase in hospi-
talisations, since these data are not yet available.
In the age group older than 10 years, who were not 
yet vaccinated, we observed a 50.0% decrease in con-
firmed rotavirus cases, suggesting an indirect pro-
tection. In many countries, the reduction in rotavirus 
disease has indeed been broader than expected based 
on vaccine coverage alone [33]. The decrease in symp-
tomatic infections in the vaccinated population most 
likely leads to a reduced chance of being exposed to 
infection for those not immunised [34].
The results of this descriptive and ecological design 
may reflect factors not related to immunisation, such 
as natural fluctuations or strain variation [41]. For 
instance, increased circulation of a specific rotavirus 
strain causing relatively mild disease could result in 
lower rotavirus related disease burden. However, after 
vaccine introduction in Belgium, G2P [4] strains, which 
are associated with more severe gastroenteritis [42,43] 
were observed to increase relative to other strains [44]. 
Also, the increased proportion of G2P [4] was seen 
more in vaccinated compared with unvaccinated chil-
dren, suggesting strain-specific differences in vaccine 
effectiveness is playing a role in altering the genotype 
distribution [44]. Despite this strain shift, our study 
shows a strong decrease in various manifestations of 
the rotavirus disease burden, confirming rotavirus vac-
cination is highly effective in reducing disease.
Hospitalisation data might be inconsistent in relation 
to rotavirus coding based on irregular laboratory con-
firmation and the potential influence of rotavirus vacci-
nation on coding practices. However, all findings were 
consistent using different independent data sources 
(including two parallel hospital databases), with dif-
ferent methods of registering diagnoses. Moreover, 
the proportion of positive tests decreased, reflecting 
lower rotavirus prevalence and we found no evidence 
of important changes in testing behaviour based on 
the number and the seasonal distribution of reim-
bursed tests. However, the reductions in rotavirus bur-
den calculated using different data sources should be 
compared with caution, as the different data sources 
did not cover the same periods. Nevertheless, epi-
demiological years 2005 to 2010 were covered by all 
data sources, and the results pointed clearly in the 
same direction. We took a conservative approach in 
identifying duplicates, assuming a maximum of one 
episode per year. This implies an underestimation of 
rotavirus burden as a second infection occurred in 4% 
of Mexican infants by 6 months of age and nearly 30% 
by 1 year of age [45]. However, because the probability 
to be symptomatic decreases with increasing number 
of previous infections [45,46] and because recurrent 
infections occurred at a slower pace [46], we believe 
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with our conservative approach we have not missed 
many episodes.
Conclusion
Rotavirus vaccination had a substantial and sustained 
public health impact up to 7 epidemiological years 
after vaccine introduction, most pronounced in the tar-
get age group but with evidence of herd immunity in 
unvaccinated age groups.
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